Diamedica Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
DiaMedica Therapeutics Inc. announced its 2026 Annual General Meeting to vote on director elections, auditor ratification, executive compensation, and a significant increase in its equity incentive plan shares.
NASDAQ
DiaMedica Therapeutics Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DiaMedica Therapeutics will hold its 2025 Annual General Meeting on May 15, 2025, to vote on the election of directors, appointment of an independent accounting firm, and executive compensation.
NASDAQ
DiaMedica Therapeutics Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF 14A: DiaMedica Therapeutics Seeks Shareholder Approval for Amended Incentive Plan, Executive Compensation
DiaMedica Therapeutics is asking shareholders to approve an amendment to its 2019 Omnibus Incentive Plan and provide advisory votes on executive compensation at the upcoming Annual General Meeting.